Author

N. Wagle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Assay:whole-exome sequencing· 5 Research Focus:cell type annotation· 4 Research Focus:differential expression· 4 Approach:experimental assay· 4 Approach:statistical model· 4 Research Focus:variant calling· 3 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

D. Kim· 4 shared O. Cohen· 4 shared A. G. Waks· 3 shared E. P. Winer· 3 shared K. J. Kowalski· 3 shared N. U. Lin· 3 shared P. Mao· 3 shared A. Bahreini· 2 shared

Activity by Year

2019-2021 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

D. Kim

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project

J. Crowdis, S. Balch, L. Sterlin, B. S. Thomas, S. Y. Camp, M. Dunphy, E. Anastasio, S. Shah, A. L. Damon, R. Ramos, D. M. Sosa, I. K. Small, B. Tomson, C. M. Nguyen, M. McGillicuddy, , E. M. Van Allen

The paper describes a patient-driven initiative that collects clinicogenomic data from metastatic prostate cancer patients, revealing consistent patient-reported data and genomic insights from cfDNA samples.

bioRxiv · Jul 9, 2021 · PreprintCancer Biology

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

Z. Li, Y. Wu, M. E. Yates, N. Tasdemir, A. Bahreini, J. Chen, K. M. Levine, N. M. Priedigkeit, S. Ali, L. Buluwela, S. Arnesen, J. Gertz, J. K. Richer, B. Troness, D. El-Ashry, , S. Oesterreich

This study identifies ESR1 mutations as drivers of breast cancer metastasis by altering cell adhesion and migration through genomic and transcriptomic reprogramming.

bioRxiv · Feb 10, 2021 · PreprintCancer Biology

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Z. Li, Y. Wu, A. Bahreini, N. M. Priedigkeit, K. Ding, C. A. Sartorius, L. Miller, M. Rosenzweig, N. Wagle, J. K. Richer, W. J. Muller, L. Buluwela, S. Ali, Y. Fang, L. Zhu, , S. Oesterreich

This study shows ESR1 mutant breast cancers exhibit basal cytokeratin expression and immune activation, linked to chromatin reprogramming and paracrine signaling.

bioRxiv · Dec 29, 2020 · PreprintCancer Biology

Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations

J. Gomez Tejeda Zanudo, P. Mao, C. Alcon, K. J. Kowalski, G. N. Johnson, G. Xu, J. Baselga, M. Scaltriti, A. Letai, J. Montero, R. Albert, N. Wagle

bioRxiv · Aug 25, 2020Cancer Biology

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

S. A. Wander, O. Cohen, X. Gong, G. N. Johnson, J. Buendia-Buendia, M. R. Lloyd, D. Kim, F. Luo, P. Mao, K. Helvie, K. J. Kowalski, U. Nayar, A. G. Waks, S. Parsons, R. Martinez, , N. Wagle

The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.

bioRxiv · Nov 28, 2019Cancer Biology

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, , N. Wagle

This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.

bioRxiv · Nov 10, 2019Cancer Biology

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

P. Mao, O. Cohen, K. J. Kowalski, J. G. Kusiel, J. E. Buendia-Buendia, M. S. Cuoco, P. Exman, S. A. Wander, A. G. Waks, U. Nayar, J. Chung, S. Freeman, O. Rozenblatt-Rosen, V. A. Miller, F. Federica Piccioni, , N. Wagle

This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.

bioRxiv · Oct 7, 2019Cancer Biology

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research

C. A. Painter, E. Jain, B. N. Tomson, M. Dunphy, R. E. Stoddard, B. S. Thomas, A. L. Damon, S. Shah, D. Kim, J. Gomez Tejeda Zanudo, J. L. Hornick, Y.-L. Chen, P. Merriam, C. P. Raut, G. D. Demetri, , N. Wagle

The paper describes the Angiosarcoma Project, a patient-partnered initiative that generates genomic data on angiosarcoma, identifying recurrent mutations and potential therapeutic targets.

bioRxiv · Aug 26, 2019Cancer Biology

Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma

L. Jerby, C. Neftel, M. E. Shore, M. J. McBride, B. Haas, B. Izar, H. R. Weissman, A. Volorio, G. Boulay, L. Cironi, A. R. Richman, L. C. Broye, J. M. Gurski, C. C. Luo, R. Mylvaganam, , A. Regev

The paper profiles synovial sarcoma tumors to show that the SS18-SSX fusion drives oncogenic programs, which are repressed by immune cells and can be targeted with HDAC and CDK4/6 inhibitors.

bioRxiv · Aug 4, 2019 · PreprintCancer Biology